Singapore O&G Ltd. - Phillip Securities 2019-02-22: Ceasing Coverage


Singapore O&G Ltd. - Ceasing Coverage

  • SINGAPORE O&G LTD. (SGX:1D8)'s FY18 Revenue exceeded our full year expectations by 7%. Adjusted PATMI met our full year estimations (excluding settlement fee receipt and legal fees from the dispute and impairment of goodwill).
  • O&G and cancer-related segments were the star performers, rising 15% y-o-y and 40% y-o-y respectively.
  • Dermatology continues as a drag to group earnings, contracting 2% y-o-y due to the slowdown in medical tourism.
  • Added one paediatrician and one dermatologist in FY18. Total number of specialists in FY18 at 14 (FY17: 12 specialists).
  • Proposed final dividend of 0.90 cents/share. FY18 dividend per share: 1.70 cents (FY17: 1.50 cents).
  • Ceasing coverage due to reallocation of internal resources.

The Positives

 Significant improvement in EBITDA

  • Significant improvement in EBITDA, due to the pick-up in profitability of O&G, cancer related and paediatric segments.
  • The O&G segment delivered 1,824 babies in FY18 as compared to 1,716 in FY17, growing 6% y-o-y (FY17: -1% y-o-y). As more specialists inch towards their breakeven point even though the total number of O&G specialists remained flat at 6. It typically takes 1-2 years for specialists to breakeven.

 Cancer-related segment revenue grew 40% y-o-y

  • Cancer-related segment revenue grew 40% y-o-y, more than offset the challenging dermatology segment and gestations costs incurred by the newly established paediatrics segment.

The Negatives

 Dermatology segment performance lacklustre due to a slowdown in medical tourism.

  • FY18 EBIT declined 5% y-o-y, and EBIT margin fell 0.9pps to 29.7%. The number of patients treated by Dr Joyce Lim was reduced because of the slowing medical tourism and her active involvement in teaching and conferences to gain visibility.
  • In a bid to expand the dermatology business, Singapore O&G recruited one new dermatologist in December 2018 who specialises in paediatric dermatology.

 The new Paediatrics segment incurred S$0.5mn ‘start-up’ losses to date.

  • One new paediatrician joined in November 2018. We expect the two existing Paediatricians to breakeven by end-FY19. The two paediatricians joined in July and November 2017.

 S$2.8mn impairment of goodwill.

  • The impairment relates to the excess of the carrying amount of the cash generating unit (CGU) over the recoverable amount of the CGU as at year end of the Dermatology segment, using a DCF valuation model and projected over 7 years plus terminal value. Current accounting standards require impairment instead of amortisation.


  • With a gradual recovery in birth rates in Singapore, coupled with the Group’s ability to consistently gain market share in live births in Singapore, we expect the O&G segment to continue registering better growth.
  • We also expect the cancer-related segment to support Group’s FY19e profitability amidst persistent headwinds –
    1. sluggish birth rate and
    2. structural slowdown in medical tourism.
  • Profitability from the O&G and Cancer-related segment should improve as more doctors breakeven and gain more patient load. The Group is actively seeking suitable doctors to join its team to further grow its four business pillars. New doctors typically take 1 – 2.5 years to break even.
  • The Group has a robust balance sheet with zero debt and a cash position of S$21.5mn (c.13% of its market cap).

Ceasing coverage

  • Our most recent rating from our 13 August 2018 report (see Singapore O&G Ltd - Gaining Market Share), was BUY with a target price of $0.420. We are ceasing coverage on this counter due to the reallocation of internal resources.

S$1.25mn non-recurring item booked in 2Q18

  • Refer to the announcement dated 6 Mar-18, Singapore O&G has received the settlement amount of S$1.25mn for a settlement related to a dispute with its former Lead Independent Director, Mr. Christopher Chong Meng Tak. See Singapore O&G's announcements

Tin Min Ying Phillip Securities Research | 2019-02-22
SGX Stock Analyst Report NOT RATED MAINTAIN BUY 99998 SAME 0.420